Neuro Bio

Neuro Bio is a private, preclinical-stage biotech pioneering a disruptive hypothesis for Alzheimer's disease (AD) that challenges the dominant amyloid dogma. The company's core discovery is the T14 peptide, which it posits triggers an aberrant, developmental-like process in specific vulnerable neurons, driving neurodegeneration upstream of amyloid plaque formation. This mechanism informs a dual strategy: a diagnostic pipeline for early detection of T14 in nasal secretions and saliva, and a therapeutic pipeline led by NBP-14, an antagonist of T14. The company is also exploring applications of its platform in oncology, dermatology, and diabetic retinopathy, indicating a broader platform potential.

Platform centered on the T14 peptide, a 14mer identified as a key toxic driver of neurodegeneration via an aberrant developmental mechanism. The platform enables diagnostic detection of T14 and therapeutic intervention with T14 antagonists, with applications spanning multiple disease areas.

Neuro Bio competes in the highly crowded and competitive Alzheimer's therapeutic and diagnostic landscape, dominated by large pharma and well-funded biotechs focused on amyloid, tau, inflammation, and other targets. Its differentiation lies in its novel upstream mechanism, but it must prove clinical superiority or complementary action to established approaches.